Effects of Ipragliflozin on the Diurnal Profiles of Plasma Glucose and 3-hydroxybutyrate in Patients with Type 2 Diabetes

Trial Profile

Effects of Ipragliflozin on the Diurnal Profiles of Plasma Glucose and 3-hydroxybutyrate in Patients with Type 2 Diabetes

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jul 2015

At a glance

  • Drugs Ipragliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 23 Jul 2015 New trial record
    • 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top